

# Renier J Brentjens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4006693/publications.pdf>

Version: 2024-02-01

108  
papers

17,470  
citations

61857

43  
h-index

46693

89  
g-index

110  
all docs

110  
docs citations

110  
times ranked

15464  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multipurposing CARs: Same engine, different vehicles. <i>Molecular Therapy</i> , 2022, 30, 1381-1395.	3.7	9
2	Engineering CAR-T cells to activate small-molecule drugs in situ. <i>Nature Chemical Biology</i> , 2022, 18, 216-225.	3.9	39
3	CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. , 2022, 10, e004128.		18
4	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2022, 28, 713-723.	15.2	117
5	Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 342-355.	12.5	113
6	Frontiers in cancer immunotherapy—a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1489, 30-47.	1.8	39
7	Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 3268-3271.	3.3	21
8	Chimeric Antigen Receptor—Modified Immune Effector Cell Therapies. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 90-91.	1.0	0
9	Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition. <i>Frontiers in Immunology</i> , 2021, 12, 663379.	2.2	20
10	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti—PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	7.7	222
11	Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021, 5, 3397-3406.	2.5	59
12	Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 377-387.	1.8	17
13	Human cytomegalovirus expands a CD8 <sup>+</sup> T cell population with loss of BCL11B expression and gain of NK cell identity. <i>Science Immunology</i> , 2021, 6, eabe6968.	5.6	25
14	Engineering strategies to overcome the current roadblocks in CAR T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 147-167.	12.5	786
15	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810.		5
16	CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function. <i>Nature Communications</i> , 2020, 11, 6171.	5.8	20
17	Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. <i>Cancers</i> , 2020, 12, 2175.	1.7	17
18	Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. <i>Nature Communications</i> , 2020, 11, 6298.	5.8	82

#	ARTICLE	IF	CITATIONS
19	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2160-2169.	1.3	11
20	CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?. <i>Cancer Cell</i> , 2020, 37, 761-763.	7.7	0
21	Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. <i>British Journal of Haematology</i> , 2020, 190, 45-51.	1.2	51
22	Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells. <i>Cancer Immunology Research</i> , 2020, 8, 732-742.	1.6	16
23	Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2020, 1, 146-154.	2.6	114
24	Enhancing CAR T cell efficacy: the next step toward a clinical revolution?. <i>Expert Review of Hematology</i> , 2020, 13, 533-543.	1.0	10
25	Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.	2.5	101
26	Application of CAR T cells for the treatment of solid tumors. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 293-327.	0.9	15
27	CARs of the future. <i>American Journal of Hematology</i> , 2019, 94, S55-S58.	2.0	10
28	CAR T cell therapy: Full speed ahead. <i>Hematological Oncology</i> , 2019, 37, 95-100.	0.8	131
29	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. <i>Cancer Immunology Research</i> , 2019, 7, 1047-1053.	1.6	59
30	CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. <i>Cancer Cell</i> , 2019, 35, 473-488.e6.	7.7	159
31	GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	229
32	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. <i>Blood</i> , 2019, 134, 2361-2368.	0.6	190
33	Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia. <i>EBioMedicine</i> , 2019, 39, 173-181.	2.7	47
34	Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1135-1141.	2.0	60
35	Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 449-459.	13.9	1,951
36	Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector. <i>Molecular Therapy</i> , 2018, 26, 1447-1456.	3.7	77

#	ARTICLE	IF	CITATIONS
37	Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 1717-1721.	0.6	6
38	Dawn of chimeric antigen receptor T cell therapy in non-Hodgkin Lymphoma. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e23.	0.6	1
39	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
40	Tumors evading CARs—the chase is on. <i>Nature Medicine</i> , 2018, 24, 1492-1493.	15.2	32
41	Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 10, 371-378.	1.8	24
42	Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. <i>Cell Reports</i> , 2018, 23, 2130-2141.	2.9	233
43	CAR T cells, immunologic and cellular therapies in hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 115-116.	0.7	1
44	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. <i>Nature Biotechnology</i> , 2018, 36, 847-856.	9.4	564
45	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. <i>Molecular Therapy</i> , 2018, 26, 1896-1905.	3.7	65
46	Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2018, 8, 958-971.	7.7	594
47	Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity. <i>Blood</i> , 2018, 132, 3492-3492.	0.6	13
48	Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 333-334.	12.5	10
49	Development of CAR T cells designed to improve antitumor efficacy and safety. , 2017, 178, 83-91.		90
50	Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. <i>Scientific Reports</i> , 2017, 7, 10541.	1.6	288
51	Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1429-1437.	2.3	18
52	Adoptive T-Cell Therapy for Solid Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 193-204.	1.8	44
53	Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM. <i>Blood</i> , 2017, 130, 742-742.	0.6	92
54	Enhancing CAR T Cell Anti-Tumor Efficacy through Secreted Single Chain Variable Fragment (scFv) Immune Checkpoint Blockade. <i>Blood</i> , 2017, 130, 842-842.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Medical management of side effects related to CAR T cell therapy in hematologic malignancies. <i>Expert Review of Hematology</i> , 2016, 9, 511-513.	1.0	43
56	CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. <i>Blood</i> , 2016, 127, 3312-3320.	0.6	346
57	Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells. <i>Cytotherapy</i> , 2016, 18, 1393-1409.	0.3	79
58	Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. <i>Biochemical Society Transactions</i> , 2016, 44, 412-418.	1.6	182
59	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. <i>Cell</i> , 2016, 167, 405-418.e13.	13.5	204
60	At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies. <i>Journal of Leukocyte Biology</i> , 2016, 100, 1255-1264.	1.5	10
61	Toxicity and management in CAR T-cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16011.	2.0	686
62	Driving CAR T-cells forward. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 370-383.	12.5	492
63	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	12.5	909
64	Novel immunotherapies in lymphoid malignancies. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 25-40.	12.5	224
65	CD33-Directed Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 2825-2825.	0.6	9
66	IL-18 Secreting CAR T Cells Enhance Cell Persistence, Induce Prolonged B Cell Aplasia and Eradicate CD19+ Tumor Cells without Need for Prior Conditioning. <i>Blood</i> , 2016, 128, 816-816.	0.6	28
67	The Development of a qPCR Assay for the Evaluation of the Dendritic Cell Chimeric Antigen Receptor Transcriptome. <i>Blood</i> , 2016, 128, 5895-5895.	0.6	0
68	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. <i>Blood</i> , 2015, 125, 199-205.	0.6	109
69	A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 102.	1.8	221
70	CD19 CAR Therapy for Acute Lymphoblastic Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e360-e363.	1.8	45
71	IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i> in vivo</i> . <i>Oncolmmunology</i> , 2015, 4, e994446.	2.1	336
72	Overcoming Antigen Escape with CAR T-cell Therapy. <i>Cancer Discovery</i> , 2015, 5, 1238-1240.	7.7	69

#	ARTICLE	IF	CITATIONS
73	Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression. <i>Molecular Therapy</i> , 2015, 23, 769-778.	3.7	195
74	CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?. <i>Immunotherapy</i> , 2015, 7, 545-561.	1.0	26
75	Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL. <i>Blood</i> , 2015, 126, 2533-2533.	0.6	10
76	Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL. <i>Blood</i> , 2015, 126, 682-682.	0.6	37
77	CAR T Cells in Acute Lymphoblastic Leukemia. , 2015, 12, .		0
78	Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. <i>Science Translational Medicine</i> , 2014, 6, 224ra25.	5.8	2,069
79	Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: A possible mechanism for the origin of leukemia in donor cells. <i>Leukemia Research Reports</i> , 2014, 3, 38-41.	0.2	14
80	CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia. <i>Science Translational Medicine</i> , 2013, 5, 177ra38.	5.8	1,748
81	Chronic Myeloid Leukemia After Adjuvant Treatment For Breast Cancer: Is It Therapy Related?. <i>Blood</i> , 2013, 122, 2740-2740.	0.6	1
82	Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy. <i>Blood</i> , 2013, 122, 69-69.	0.6	5
83	Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL. <i>Blood</i> , 2013, 122, 874-874.	0.6	5
84	Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL. <i>Blood</i> , 2012, 120, 1797-1797.	0.6	6
85	CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT. <i>Blood</i> , 2012, 120, 353-353.	0.6	6
86	Constitutive Expression of CD40L by CAR-Modified Tumor Targeted T Cells Enhances Anti-Tumor Efficacy Both in Vitro and in Vivo. <i>Blood</i> , 2012, 120, 4120-4120.	0.6	1
87	Conditioning Intensity and T Cell Dose Determine Efficacy of CD19-Targeted T Cell-Mediated Tumor Eradication in an Immunocompetent Mouse Model of B-ALL.. <i>Blood</i> , 2012, 120, 2613-2613.	0.6	0
88	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2482-2482.	0.6	1
89	Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19-28z CAR-Targeted T Cells. <i>Blood</i> , 2012, 120, 3566-3566.	0.6	1
90	Highly Sensitive Bioluminescence in Vivo Imaging Enables Individualized Preclinical Treatment Trials On Patients ALL Tumor Cells Growing in Mice.. <i>Blood</i> , 2012, 120, 2602-2602.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy. <i>Blood</i> , 2012, 120, 3556-3556.	0.6	0
92	Abstract Title Submitted by Hollie Pegram to the 2012 ASH Annual Meeting: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12. <i>Blood</i> , 2012, 120, 1907-1907.	0.6	0
93	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. <i>Blood</i> , 2011, 118, 4817-4828.	0.6	1,135
94	Tumor Specific T Cells Modified to Secrete IL-12 Eradicate Systemic Tumors in the Absence of Prior Toxic Chemotherapy Conditioning Regimens. <i>Blood</i> , 2011, 118, 3120-3120.	0.6	0
95	Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History. <i>Blood</i> , 2011, 118, 1765-1765.	0.6	0
96	In Vivo comparison of 3 Suicide Gene-Prodrug Combinations in a Mouse Graft-Versus-Host-Disease Model. <i>Blood</i> , 2011, 118, 3121-3121.	0.6	0
97	Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center. <i>Blood</i> , 2011, 118, 4433-4433.	0.6	0
98	Enhanced Antitumor Efficacy of MUC-16 Targeted T Cells Further Modified to Constitutively Express the IL-12 Cytokine in a Syngeneic Model of Ovarian Cancer. <i>Blood</i> , 2011, 118, 4176-4176.	0.6	0
99	Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice. <i>Blood</i> , 2010, 116, 2092-2092.	0.6	1
100	Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3595-3595.	0.6	0
101	CD19 Targeted Cord Blood Derived T Cells for Cancer Immunotherapy. <i>Blood</i> , 2010, 116, 3767-3767.	0.6	0
102	Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. <i>Nature Medicine</i> , 2009, 15, 338-344.	15.2	120
103	Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo. <i>Blood</i> , 2009, 114, 3771-3771.	0.6	1
104	Cellular therapies in acute lymphoblastic leukemia. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 375-82.	2.8	6
105	Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts. <i>Clinical Cancer Research</i> , 2007, 13, 5426-5435.	3.2	398
106	Novel approaches to immunotherapy for B-cell malignancies. <i>Psychophysiology</i> , 2005, 4, 64-72.	1.1	2
107	Novel approaches to immunotherapy for B-cell malignancies. <i>Current Oncology Reports</i> , 2004, 6, 339-347.	1.8	4
108	Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. <i>Nature Medicine</i> , 2003, 9, 279-286.	15.2	586